|
AU2018378465A1
|
|
Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
|
|
EP3703738A1
|
|
Botulinum toxin formulations and methods of use thereof in plantar fasciitis with extended duration of effect
|
|
WO2019046311A1
|
|
Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
|
|
BR112019024082A2
|
|
TREATMENT METHODS FOR CERVICAL DYSTONIA
|
|
US2019262438A1
|
|
Topical Ocular Preparation of Botulinum Toxin for Use in Ocular Surface Disease
|
|
CN109069609A
|
|
Use the botulin toxin for primary mood and the disturbance of emotion of neurotransmitter
|
|
MX2018005256A
|
|
Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect.
|
|
US2016015794A1
|
|
Topical ocular preparation of botulinum toxin for use in ocular surface disease
|
|
US2016051643A1
|
|
Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
|
|
US2016030452A1
|
|
Minocycline Derivatives
|
|
WO2014066916A2
|
|
Compositions and methods for safe treatment of rhinitis
|
|
AU2013205323A1
|
|
Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
|
|
EP2841095A1
|
|
Method of treatment of wrinkles using topical chemodenervating agents
|
|
AU2013201936A1
|
|
Arginine heteromers for topical administration
|
|
US2013202636A1
|
|
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
|
AU2013201374A1
|
|
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
|
US2013197397A1
|
|
Methods and Assessment Scales for Measuring Wrinkle Severity
|
|
RS56460B1
|
|
Topical composition comprising botulinum toxin and a dye
|
|
AU2011253597A1
|
|
Multi-component biological transport systems
|
|
AU2011202928A1
|
|
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
